STAT Plus: CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed
CytoDyn CEO Nader Pourhassan is already under fire for the timing of lucrative sales of…
Author: STAT
STAT Plus: AI-centric health companies landed crucial funding in early 2020
Artificial intelligence-focused health care companies raised nearly $1 billion in funding in the first quarter…
Listen: How bad will the pandemic get? Plus: Gilead’s pricing dilemma and fighting Covid-19 in New York
What if the curve just stays flat? How much should a Covid-19 drug cost? And…
STAT Plus: Telehealth rules have shifted rapidly during the pandemic. Are the changes here to stay?
The Trump administration appears to be leaning in favor of permanently expanding telemedicine coverage as…
A snapshot of coronavirus in the U.S.: A high plateau of new cases portends more spread
For all the talk of a second wave of coronavirus cases hitting the United States…
Digital event: Confronting a Pandemic — Part 1
Editor’s note: The livesteam will be embedded below at 2:30 p.m. ET. The need to…
.jpg)
STAT Plus: Pharmalittle: Hospitals criticize feds over remdesivir supplies; Moderna starting mid-stage Covid-19 vaccine trials soon
Hello, everyone, and how are you today? We are doing just fine, thank you, given…
Opinion: Covid-19 has renewed America’s trust in its doctors. Will it fade when the pandemic is over?
I had a disturbing conversation with my younger sister about the public perception of doctors…
Opinion: Child abuse is one of many unseen harms from shutting down America’s schools
Tick tock, tick tock. In elementary school, my friend Krystal (not her real name) kept…
Photos: A peek inside one Boston hospital’s response to Covid-19
This is one in a series of reports from hospitals responding to the Covid-19 pandemic. When he…
Amazon lends its expertise — and its cash — to Covid-19 research
Shipping behemoth Amazon is increasingly throwing its weight into the pandemic response, sharing its staff’s…
Doctors lambaste federal process for distributing Covid-19 drug remdesivir
Hospitals and physicians around the country are sharply criticizing the federal government for the uneven…
Giving blood thinners to severely ill Covid-19 patients is gaining ground
Treating Covid-19 patients with medicines to prevent blood clots might help reduce deaths in patients…
Using human brain tissue in lab dishes, researchers show herpes link to Alzheimer’s
A small 3D version of the human brain develops key features of Alzheimer’s disease when…
STAT Plus: FTC approves AbbVie’s $63 million deal for Allergan amid scornful dissent
After months of deliberation, the Federal Trade Commission approved AbbVie’s (ABBV) $63 billion acquisition of…
STAT Plus: Pharmalittle: Gilead looks to widen access to remdesivir; ousted BARDA head files whistleblower complaint
Good morning, everyone, and welcome to the middle of the week. Hard to tell, though,…
Digital event: Combating Covid-19 — Part 3
Editor’s note: The live stream will be embedded below at 1 p.m ET. The pandemic…
STAT Plus: Taking a page from Apple, Fitbit launches a sweeping heart study
In a massive push to join Apple’s cardiac research ranks, Fitbit launched an ambitious study…
STAT Plus: Rebiotix unveils positive — but preliminary — data on its microbiome drug for C. diff infections
Rebiotix, one of a handful of major companies working on microbiome-based drugs, announced Wednesday that…
Opinion: Expertise can help save us from Covid-19 — if we use it right
Not long ago, I read a book about the death of expertise. As I think…
Opinion: A lesson on physician activism from Malawi’s legendary Dr. John Chiphangwi
Five years ago, I was a doctoral student studying the history of medicine in Malawi,…
Opinion: I’m a nurse in a Covid-19 unit. My hospital’s leaders frighten me more than the virus
I’ve been a nurse for almost 10 years, working mainly on a hospital’s cardiac floor….
STAT Plus: Will employers still shell out for health tech benefits in an unemployment crisis? The industry is about to find out
It’s the oldest, most reliable strategy for building a business in health tech: Sell to…
Mounting promises on Covid-19 vaccines are fueling false expectations, experts say
Vaccines to prevent Covid-19 infection are hurtling through development at speeds never before seen. But…
Gilead signals steps to widen global access to remdesivir for Covid-19 patients
Amid questions about access to remdesivir, its treatment for Covid-19, Gilead Sciences (GILD) says it…
Vaccine expert says he was punished for raising concerns about Trump’s coronavirus response, nepotism
WASHINGTON — Rick Bright, the ousted head of the Biomedical Advanced Research and Development Authority,…
The fight over facial recognition technology gets fiercer during the Covid-19 pandemic
The long-simmering debate over facial recognition technology is taking on new urgency during the pandemic,…
STAT Plus: CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions
CytoDyn chief executive Nader Pourhassan’s lucrative sale of company stock was confirmed in a regulatory…
.jpg)
STAT Plus: Pharmalittle: WHO seeking wide access to remdesivir; Gavi proposes incentives for a Covid-19 vaccine
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Doctors in Europe, New York report rare cases of pediatric inflammatory condition, possibly caused by coronavirus
Fifteen children in New York City have been hospitalized for what officials called a “multi-system…
New CRISPR-based test for Covid-19 could be a simple, cheap at-home diagnostic, scientists say
The revolutionary genetic technique better known for its potential to cure thousands of inherited diseases…
Opinion: After four years of medical school, how am I ‘nonessential’?
As the U.S began slowly grinding to a halt in February and March, we braced…
STAT Plus: Akebia’s experimental pill meets anemia, heart-safety goals in two late-stage clinical trials
Akebia Therapeutics said Tuesday that its experimental anemia pill achieved the primary efficacy and heart-safety…
Were researchers wrong to move the goalposts on remdesivir? In the end, it may not have mattered
Last Wednesday, Gilead announced that its drug, remdesivir, sped the time it took patients to…
Opinion: How biopharma companies can keep ‘feeding the beast’ in the time of coronavirus
My colleagues and I lead and support the finance function of more than 160 biopharma…
Opinion: Intubation boxes: an extra layer of safety or a false sense of security?
SARS-CoV-2, the virus that causes Covid-19, is so infectious that protecting health care workers from…
STAT Plus: Cellular ‘backpacks’ keep immune cells in attack mode against tumors
In a study recently published in Science Advances, Samir Mitragotri’s team at Harvard’s Wyss Institute…
Efforts to beat back the coronavirus are critical. They’re also making clinical trials harder
In March, a team of Chinese scientists studying whether the antiviral remdesivir was effective against…
Watch: Antibodies, immunity, and what they mean for Covid-19, explained
The immune system is no wimp. When pathogens cause illness, it kicks into high gear….
A cancer patient reconsiders her end-of-life wishes, as Covid-19 brings mortality into sharper focus
Even before she knew what kind of cancer she had, Robin Hodges knew she didn’t…
STAT Plus: With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake
Never in modern times have such high hopes for millions of lives rested on one…
STAT Plus: Orphan drugs improve health — but aren’t priced cost-effectively, study finds
As regulators approve a growing number of orphan drugs, prices for these medicines, which treat small…
Opinion: Collateral damage occurs when doctors and patients wear ‘Covid-19 blinders’
My friend Mina had a stroke at home while an infectious disease pandemic raged around…
STAT Plus: With coronavirus pandemic, venture capitalists are taking extra precautions
Venture capital firms have billions of bucks in their bank accounts. In just the past…
STAT Plus: Pharmalittle: Roche wins emergency use nod for coronavirus antibody test; blood pressure drugs don’t raise infection risk
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT Plus: Without showing any data, CytoDyn touts treatment for Covid-19 as winner — while its CEO sells stock
While Nader Pourhassan, the chief executive of drug maker CytoDyn, filed his intention to sell…
Opinion: Exercising Bayh-Dole march-in rights would handicap Covid-19 innovation
Scientists across America are working hard to develop treatments for and vaccines against the novel…
Watch: How does Gilead’s experimental drug remdesivir work against the coronavirus?
Gilead Sciences’ experimental drug remdesivir has been gaining traction as a potential Covid-19 treatment, and…
Opinion: Lifesaving ventilators will sit unused without a national data-sharing effort
In Nobel laureate Amartya Sen’s book “Poverty and Famines,” he argues that famines arise not…
Covid-19 has shuttered scientific labs. It could put a generation of researchers at risk
Scientists are skilled at tackling unexpected problems that threaten the integrity of their experiments —…